Genome pioneer Craig Venter dies at 79

Craig Venter, a key figure in sequencing the human genome and advancing synthetic biology, has died at age 79. The J. Craig Venter Institute announced his death followed a brief hospitalization for side effects from cancer treatment. Venter leaves a legacy of breakthroughs and controversies in genomics.

Craig Venter, founder of the J. Craig Venter Institute, died following a brief hospitalization for unexpected side effects from treatment of recently diagnosed cancer, the institute said. He was 79. Venter played a leading role in sequencing the human genome and later pioneered work in synthetic biology, driving both major advances and debates over commercializing research and treating science as a race. His path to prominence began after serving as a war orderly in Vietnam, which motivated him to pursue biomedical research at the National Institutes of Health in the 1980s. There, he pioneered automated sequencing of expressed sequence tags, sparking early controversy when he sought to patent them despite unknown functions. In 1998, frustrated by the pace of the publicly funded Human Genome Project launched in 1990, Venter founded Celera. His team employed shotgun sequencing—shattering DNA into random fragments for computer reassembly—contrasting the HGP's methodical Sanger approach. Both efforts announced draft human genome sequences in 2000, with publications following in 2001, though Celera initially withheld some data for commercialization. Post-genome, Venter's yacht Sorcerer II collected global seawater samples from 2004 to 2006, revealing millions of proteins and over 1,000 new families. In 2010, his team created a synthetic cell by inserting a lab-made genome into Mycoplasma capricolum, replacing its original from Mycoplasma mycoides. The cell thrived, marking a milestone in synthetic life, though critics questioned its practical value. Venter later worked on minimal genomes, uncovering many essential genes of unknown function. His enormous impact on genomics, biology, and biodiversity will shape scientific history.

Related Articles

Illustration of UC San Diego researchers' CRISPR pPro-MobV system spreading through bacterial biofilms to disable antibiotic resistance genes in a lab setting.
Image generated by AI

UC San Diego researchers describe a gene-drive-like CRISPR system designed to reduce antibiotic resistance in bacteria

Reported by AI Image generated by AI Fact checked

Researchers at the University of California San Diego report they have developed a second-generation CRISPR-based “Pro-Active Genetics” system, called pPro-MobV, that is designed to spread between bacteria and disable antibiotic-resistance genes, including inside hard-to-treat biofilms.

Scientists have produced the first living synthetic bacterial cells by transplanting a synthetic genome into bacteria whose own genomes were destroyed. The team at the J. Craig Venter Institute calls these revived cells 'zombie cells'. The method addresses challenges in synthetic biology by ensuring control over the new genome.

Reported by AI

After 30 years in the United States, world-leading computational biologist Bao Zhirong has taken up a full-time position at the Southern University of Science and Technology in Shenzhen. Renowned for his cancer genomics research, he will study brain circuits for insights into autism at his new lab. The move underscores the appeal of China's research environment.

A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.

Reported by AI

Renowned forensic scientist Henry C. Lee passed away on Friday at his home in Henderson, Nevada. He was 87. His family and the University of New Haven, where he taught for more than 50 years, announced the news.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline